Literature DB >> 29701096

The role of grade in local recurrence and the disease-specific survival in chondrosarcomas.

M K Laitinen1, J D Stevenson2, M C Parry2, V Sumathi2, R J Grimer2, L M Jeys2.   

Abstract

Aims: The purpose of this study was to describe the effect of histological grade on disease-specific survival in patients with chondrosarcoma. Patients and
Methods: A total of 343 patients with a chondrosarcoma were included. The histological grade was assessed on the initial biopsy and on the resection specimen. Where the histology showed a mixed grade, the highest grade was taken as the definitive grade. When only small focal areas showed higher grade, the final grade was considered as both.
Results: The concordance between the highest preoperative biopsy grading and the highest final grading of the resection specimen in total was only 43% (146/343). In 102 specimens (30%), a small number of cells or focal areas of higher grade were observed in contrast to the main histology. The disease-specific survival, stratified according to the predominant histological grade, showed greater variation than when stratified according to the highest grade seen in the resection specimen.
Conclusion: The diagnostic biopsy in chondrosarcoma is unreliable in assessing the definitive grade and the malignant potential of the tumour. When categorizing the grade of the resection specimen, the prognosis for local recurrence and disease-specific survival should be based on the highest grade seen, even when seen in only a few cells. Cite this article: Bone Joint J 2018;100-B:662-6.

Entities:  

Keywords:  Biopsy; Bone neoplasm; Chondrosarcoma; Prognosis

Mesh:

Year:  2018        PMID: 29701096     DOI: 10.1302/0301-620X.100B5.BJJ-2017-1243.R1

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  7 in total

Review 1.  Percutaneous biopsy of musculoskeletal tumors and the potential for needle tract seeding: technical considerations, current controversies, and outcomes.

Authors:  Cara Lai; Jeremiah R Long; Brandon T Larsen; Jose M Iturregui; Benjamin K Wilke; Krista A Goulding
Journal:  Skeletal Radiol       Date:  2022-10-18       Impact factor: 2.128

2.  Chondrosarcoma of bone in children and adolescents.

Authors:  Yoichi Kaneuchi; Tomohiro Fujiwara; Yusuke Tsuda; Shinichirou Yoshida; Jonathan D Stevenson; Adesegun Abudu
Journal:  J Child Orthop       Date:  2020-08-01       Impact factor: 1.548

3.  The changing face of central chondrosarcoma of bone. One UK-based orthopaedic oncology unit's experience of 33 years referrals.

Authors:  A Mark Davies; Anish Patel; Rajesh Botchu; Christine Azzopardi; Steven James; Lee Jeys
Journal:  J Clin Orthop Trauma       Date:  2021-02-27

4.  The utility of 18F-FDG PET and PET/CT in the diagnosis and staging of chondrosarcoma: a meta-analysis.

Authors:  Qingyu Zhang; Yongming Xi; Dong Li; Zenong Yuan; Jun Dong
Journal:  J Orthop Surg Res       Date:  2020-06-22       Impact factor: 2.359

5.  Can MRI differentiate between atypical cartilaginous tumors and high-grade chondrosarcoma? A systematic review.

Authors:  Claudia Deckers; Maarten J Steyvers; Gerjon Hannink; H W Bart Schreuder; Jacky W J de Rooy; Ingrid C M Van Der Geest
Journal:  Acta Orthop       Date:  2020-05-20       Impact factor: 3.717

6.  Importance of Skeletal Staging in Chondrosarcoma of Bone: Results of Survey on Current Practices Among Musculoskeletal Oncologists.

Authors:  Ashish Gulia; Srinath Gupta; Vineet Kurisunkal; Ajay Puri
Journal:  Indian J Orthop       Date:  2020-05-06       Impact factor: 1.251

7.  Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations.

Authors:  Iben Lyskjaer; Christopher Davies; Anna-Christina Strobl; Joanna Hindley; Steven James; Radhesh K Lalam; William Cross; Geoff Hide; Kenneth S Rankin; Lee Jeys; Roberto Tirabosco; Jonathan Stevenson; Paul O'Donnell; Paul Cool; Adrienne M Flanagan
Journal:  Mol Oncol       Date:  2021-09-30       Impact factor: 6.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.